http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104471393-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-1006 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N15-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2013-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104471393-B |
| titleOfInvention | Method, reagent and kit for detecting minimal residual disease |
| abstract | The present invention relates to the field of minimal residual disease (MRD) diagnostics, which is increasingly used to evaluate the efficacy of treatment in patients with hematological malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic Cellular Leukemia (B‑CLL) and Multiple Myeloma (MM). The unique reagent composition offered features carefully selected and thoroughly tested antibody combinations that achieve at least 10 ‑4 and even as low as 10‑5 sensitivity. The invention also provides diagnostic kits and methods for detecting MRD. |
| priorityDate | 2012-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 98.